Acarbose improves health and lifespan in aging HET3 mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
To follow‐up on our previous report that acarbose (ACA), a drug that blocks postprandial glucose spikes, increases mouse lifespan, we studied ACA at three doses: 400, 1,000 (the original dose), and 2,500 ppm, using genetically heterogeneous mice at three sites. Each dose led to a significant change (by log‐rank test) in both sexes, with larger effects in males, consistent with the original report. There were no significant differences among the three doses. The two higher doses produced 16% or 17% increases in median longevity of males, but only 4% or 5% increases in females. Age at the 90th percentile was increased significantly (8%–11%) in males at each dose, but was significantly increased (3%) in females only at 1,000 ppm. The sex effect on longevity is not explained simply by weight or fat mass, which were reduced by ACA more in females than in males. ACA at 1,000 ppm reduced lung tumors in males, diminished liver degeneration in both sexes and glomerulosclerosis in females, reduced blood glucose responses to refeeding in males, and improved rotarod performance in aging females, but not males. Three other interventions were also tested: ursolic acid, 2‐(2‐hydroxyphenyl) benzothiazole (HBX), and INT‐767; none of these affected lifespan at the doses tested. The acarbose results confirm and extend our original report, prompt further attention to the effects of transient periods of high blood glucose on aging and the diseases of aging, including cancer, and should motivate studies of acarbose and other glucose‐control drugs in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“UM‐HET3 mice were produced at each of the three test sites as previously described (Harrison et al., 2009; Miller et al., 2011; Strong et al., 2008), where environmental conditions are presented in detail.”
BackgroundMethodSelf-citationBile acids as regulatory molecules
Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., & Dent, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900007-jlr200 · Cited by 694
Harrison, D. E., Strong, R., Allison, D. B., Ames, B. N., Astle, C. M., Atamna, H., Fernandez, E., Flurkey, K., Javors, M. A., Nadon, N. L., et al. (2014) · Aging Cell · doi:10.1111/acel.12170 · Cited by 445
Self-citationStrong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., Fernandez, E., Flurkey, K., Hamilton, K. L., Lamming, D. W., et al. (2016) · Aging Cell · doi:10.1111/acel.12496 · Cited by 362 · cited 2×
“Acarbose and 17‐α‐estradiol (17aE2) also extend mouse lifespans, with stronger (ACA) or exclusive (17aE2) effects in males (Harrison et al., 2014; Strong et al., 2016).”
BackgroundSelf-citationNordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice
Strong, R., Miller, R. A., Astle, C. M., Floyd, R. A., Flurkey, K., Hensley, K. L., Javors, M. A., Leeuwenburgh, C., Nelson, J. F., Ongini, E., et al. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00414.x · Cited by 349
Self-citationYuan, R., Meng, Q., Nautiyal, J., Flurkey, K., Tsaih, S.-W., Krier, R., Parker, M. G., Harrison, D. E., & Paigen, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121113109 · Cited by 121 · cited 1×
“Yuan et al. (2012) showed that female sexual maturation co‐regulated with lifespan via IGF1, while Garratt, Bower, Garcia, and Miller (2017) showed that gonadal hormones were important in differences between males and females on several effects of ACA, including glucose homeostasis, although…”
BackgroundSelf-citation
Cited by
The metabolic roots of senescence: mechanisms and opportunities for intervention
Wiley, C. D., & Campisi, J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00483-8 · Cited by 691
Fang, E. F., Xie, C., Schenkel, J. A., Wu, C., Long, Q., Cui, H., Aman, Y., Frank, J., Liao, J., Zou, H., et al. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101174 · Cited by 675
Epigenetic regulation of aging: implications for interventions of aging and diseases
Wang, K., Liu, H., Hu, Q., Wang, L., Liu, J., Zheng, Z., Zhang, W., Ren, J., Zhu, F., & Liu, G.-H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01211-8 · Cited by 663
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Smith, B. J., Miller, R. A., Ericsson, A. C., Harrison, D. C., Strong, R., & Schmidt, T. M. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1494-7 · Cited by 349
Self-citationThe road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Yu, D., Tomasiewicz, J. L., Yang, S. E., Miller, B. R., Wakai, M. H., Sherman, D. S., Cummings, N. E., Baar, E. L., Brinkman, J. A., Syed, F. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.084 · Cited by 98
Strong, R., Miller, R. A., Cheng, C. J., Nelson, J. F., Gelfond, J., Allani, S. K., Diaz, V., Dorigatti, A. O., Dorigatti, J., Fernandez, E., et al. (2022) · Aging Cell · doi:10.1111/acel.13724 · Cited by 76
Self-citationHarrison, D. E., Strong, R., Reifsnyder, P., Rosenthal, N., Korstanje, R., Fernandez, E., Flurkey, K., Ginsburg, B. C., Murrell, M. D., Javors, M. A., et al. (2023) · GeroScience · doi:10.1007/s11357-023-01011-0 · Cited by 56
Self-citationCompression of morbidity by interventions that steepen the survival curve
Yang, Y., Mayo, A., Levy, T., Raz, N., Shenhar, B., Jarosz, D. F., & Alon, U. (2025) · Nature Communications · doi:10.1038/s41467-025-57807-5 · Cited by 18
Jiang, Z., He, Q., Wezeman, J., Darvas, M., & Ladiges, W. (2024) · GeroScience · doi:10.1007/s11357-024-01198-w · Cited by 10
Lewis, C. J., & de Grey, A. D. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2330425 · Cited by 10
“Rapamycin has been found to be more effective in conjunction with other beneficial compounds including the diabetes drug acarbose and the ACE inhibitor Captopril [24], both of which have healthspan-promoting benefits on their own in mice and C. elegans, respectively [25–28].”
Metadata
- Authors
- Harrison, D. E., Strong, R., Alavez, S., Astle, C. M., DiGiovanni, J., Fernandez, E., Flurkey, K., Garratt, M., Gelfond, J. A. L., Javors, M. A., Levi, M., Lithgow, G. J., Macchiarini, F., Nelson, J. F., Sukoff Rizzo, S. J., Slaga, T. J., Stearns, T., Wilkinson, J. E., & Miller, R. A.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2019-01-27
- Volume
- 18
- Issue
- 2
- Pages
- e12898-e12898
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2912297883
- Cited by
- 141
- References
- 6
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.